Aligos Therapeutics (NASDAQ:ALGS) Issues Earnings Results

Aligos Therapeutics (NASDAQ:ALGS) released its quarterly earnings results on Wednesday. The company reported ($3.07) EPS for the quarter, missing the consensus estimate of ($2.15) by ($0.92), Zacks reports. The firm had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.00 million. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same quarter in the prior year, the business earned ($10.25) earnings per share.

Aligos Therapeutics Stock Performance

Shares of ALGS traded up $0.27 during midday trading on Friday, hitting $10.19. The company had a trading volume of 108,249 shares, compared to its average volume of 39,795. The company’s 50-day simple moving average is $9.81 and its 200-day simple moving average is $12.63. The firm has a market capitalization of $32.61 million, a P/E ratio of -0.50 and a beta of 2.11. Aligos Therapeutics has a 1 year low of $6.76 and a 1 year high of $30.00.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research report on Thursday.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).